

What is cholesterol?

Cholesterol is a fatty substance found in your blood. Everyone needs some cholesterol but if you have too much, it can lead to health problems. Having too much cholesterol can run in families, but it is usually caused by:

- Eating fatty food
- Not exercising enough
- Being overweight
- Smoking
- Drinking alcohol

How does this link to cardiovascular disease?

Cardiovascular disease is a term used to describe a range of conditions that affect the heart or blood vessels. Cholesterol can block your blood vessels, which can lead to a heart attack or stroke.

Cardiovascular disease: key facts

Cardiovascular disease is the leading cause of death and disability worldwide.¹ Of deaths related to cardiovascular disease, about 80% are due to a heart attack or stroke.¹

1. World Health Organization (WHO). Global Status Report on Noncommunicable Diseases. Geneva 2014; <http://www.who.int/nmh/publications/ncd-status-report-2014/en/>.

What should I do if I am interested in learning more about the VESALIUS-CV clinical research study?

The study team will be able to give you more information about whether you meet the criteria to take part in the clinical research study. Feel free to speak to your doctor before getting in touch via the contact details below.

You can contact the VESALIUS-CV clinical research study team by:

Telephone

Email



Do you have high cholesterol or are you at high risk for heart attack or stroke for other reasons?

Learn more about a clinical research study that could benefit future patients at risk

Amgen Protocol Number: 20170625, amendment 2, dated 28 February 2020
ClinicalTrials.gov Identifier: NCT03872401 | EudraCT Number: 2018-004565-14 © Amgen Inc. All rights reserved.
Vesalius-CV_Recruitment Flyer_17-Apr-20_v1.0_UK
Veeva Document Number: GB-REP-0520-00015

Why are clinical research studies being carried out?

Clinical research studies are very important to test how safe new treatments are, and how well they work. Clinical research studies help us to further understand medical conditions and how best to care for patients.

What is the VESALIUS-CV clinical research study?

The VESALIUS-CV clinical research study will examine the effects of evolocumab, the investigational study drug, in people who are at high risk of a cardiovascular event such as a heart attack or stroke. The investigational study drug works by lowering the amount of cholesterol in blood.

How will the VESALIUS-CV clinical research study work?

At least 12,000 people are being selected to take part in this clinical research study. It is expected to last for a minimum of 4 years.

Participants will be placed at random into one of two groups:

- One group will take the investigational study drug
- The other group will take placebo

What is a placebo?

A placebo looks the same as the investigational study drug but does not contain any active ingredients.

- The investigational study drug and placebo are given by injection, under the skin every 2 weeks.
- Everyone who takes part will continue to take any medication that they are currently being prescribed, including statins.

Information about this clinical research study to help you decide if you want to participate

Participation in this important clinical research study will help inform how to prevent heart attacks and/or strokes and provide the best possible care for future patients at risk.

Information from the clinical research study might also help with the development of new treatment options.

No-one can guarantee if participation in this clinical research study will help you. Your condition may get better but it could stay the same, or even get worse.

Throughout your time in the clinical research study, you will have full support from the study doctor and study staff, who will be available to help with any concerns or questions you may have.

How do I know if I qualify to take part in the VESALIUS-CV clinical research study?

This clinical research study is open to men (aged 50–79 years old) and women (aged 55–79 years old), who have raised cholesterol levels and are at high risk of a cardiovascular event (such as a heart attack or stroke). To find out if you meet the full criteria, check with your doctor or contact the VESALIUS-CV clinical research study team using the phone number or email address below.

If you decide that you would like to take part, the study doctor and study staff will perform necessary assessments to make sure that you meet all the study requirements.

How much of my time will it take if I participate in the VESALIUS-CV clinical research study?

You will need to attend some appointments with your study doctor. To begin with, you will attend a screening appointment and if you meet the criteria for inclusion in the study, you will be asked to attend a separate visit known as 'Day 1', which is the first day of treatment.

Following screening and Day 1:

- You will need to attend an appointment every 16 weeks (approximately every 3.5 months).
- You will take the study drug every 2 weeks, but you will be able to do this by yourself at home, without an appointment.

Don't worry: the study team will provide you with full training on how to take the study medication and will always be available to answer any questions you may have.